EP0863704A4 - Stimulation of cell-mediated immune responses by targeted particulate genetic immunization - Google Patents

Stimulation of cell-mediated immune responses by targeted particulate genetic immunization

Info

Publication number
EP0863704A4
EP0863704A4 EP96933987A EP96933987A EP0863704A4 EP 0863704 A4 EP0863704 A4 EP 0863704A4 EP 96933987 A EP96933987 A EP 96933987A EP 96933987 A EP96933987 A EP 96933987A EP 0863704 A4 EP0863704 A4 EP 0863704A4
Authority
EP
European Patent Office
Prior art keywords
stimulation
cell
immune responses
mediated immune
genetic immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96933987A
Other languages
German (de)
French (fr)
Other versions
EP0863704A1 (en
Inventor
Louis D Falo Jr
Kenneth L Rock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
University of Pittsburgh
Original Assignee
Dana Farber Cancer Institute Inc
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, University of Pittsburgh filed Critical Dana Farber Cancer Institute Inc
Publication of EP0863704A1 publication Critical patent/EP0863704A1/en
Publication of EP0863704A4 publication Critical patent/EP0863704A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP96933987A 1995-09-28 1996-09-27 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization Withdrawn EP0863704A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53555695A 1995-09-28 1995-09-28
PCT/US1996/015728 WO1997011605A1 (en) 1995-09-28 1996-09-27 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
US535556 2000-03-27

Publications (2)

Publication Number Publication Date
EP0863704A1 EP0863704A1 (en) 1998-09-16
EP0863704A4 true EP0863704A4 (en) 2003-09-10

Family

ID=24134735

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96933987A Withdrawn EP0863704A4 (en) 1995-09-28 1996-09-27 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization

Country Status (15)

Country Link
EP (1) EP0863704A4 (en)
JP (1) JPH11512724A (en)
KR (1) KR19990063672A (en)
CN (1) CN1201369A (en)
AU (1) AU716497B2 (en)
BG (1) BG102355A (en)
CA (1) CA2233278A1 (en)
CZ (1) CZ92998A3 (en)
HU (1) HUP9802651A3 (en)
NO (1) NO981386L (en)
NZ (1) NZ319891A (en)
PL (1) PL325953A1 (en)
SK (1) SK40198A3 (en)
TR (1) TR199800573T2 (en)
WO (1) WO1997011605A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3210997A (en) * 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6287569B1 (en) * 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
WO1999041368A2 (en) * 1998-02-11 1999-08-19 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
JP2003523721A (en) 1998-12-31 2003-08-12 カイロン コーポレイション Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof
WO2000063385A2 (en) * 1999-04-21 2000-10-26 Powderject Vaccines, Inc. Nucleic acid immunization
ATE411044T1 (en) * 2001-03-30 2008-10-15 Ghc Res Dev Corp MONOCYTE SPECIFIC PARTICULATE ADMINISTRATION VEHICLE
CA2634992C (en) 2001-07-05 2012-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US11529414B2 (en) 2020-06-23 2022-12-20 Orbis Health Solutions, Llc Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 15 April 1995 (1995-04-15), ZAROZINSKI C C ET AL: "Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein.", XP002238694, Database accession no. NLM7706740 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 4 September 1995 (1995-09-04), FOMSGAARD A: "[Genetic immunization--"the biological equivalent of cold fusion"?]", XP002238693, Database accession no. NLM7676526 *
FYNAN E F ET AL: "DNA VACCINES: PROTECTIVE IMMUNIZATIONS BY PARENTERAL, MUCOSAL, AND GENE-GUN INOCULATIONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, 1 December 1993 (1993-12-01), pages 11478 - 11482, XP000770731, ISSN: 0027-8424 *
HEYDENBURG FULLER D ET AL: "A QUALITATIVE PROGRESSION IN HIV TYPE 1 GLYCOPROTEIN 120-SPECIFIC CYTOTOXIC CELLULAR AND HUMORAL IMMUNE RESPONSES IN MICE RECEIVING ADNA-BASED GLYCOPROTEIN 120 VACCINE", AIDS RESEARCH AND HUMAN RETROVIRUSES, NEW YORK, NY, US, vol. 10, no. 11, 1 November 1994 (1994-11-01), pages 1433 - 1441, XP000572444, ISSN: 0889-2229 *
JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 APR 1995, vol. 154, no. 8, 15 April 1995 (1995-04-15), pages 4010 - 4017, ISSN: 0022-1767 *
LAI W C: "PROTECTION AGAINST MYCOPLASMA PULMONIS INFECTION BY GENETIC VACCINATION", DNA AND CELL BIOLOGY, NEW YORK, NY, US, vol. 14, no. 7, 1 July 1995 (1995-07-01), pages 643 - 651, XP000575588, ISSN: 1044-5498 *
See also references of WO9711605A1 *
UGESKRIFT FOR LAEGER. DENMARK 4 SEP 1995, vol. 157, no. 36, 4 September 1995 (1995-09-04), pages 4932 - 4936, ISSN: 0041-5782 *

Also Published As

Publication number Publication date
EP0863704A1 (en) 1998-09-16
HUP9802651A2 (en) 1999-02-01
SK40198A3 (en) 1998-11-04
CA2233278A1 (en) 1997-04-03
WO1997011605A1 (en) 1997-04-03
CZ92998A3 (en) 1998-09-16
NO981386D0 (en) 1998-03-26
HUP9802651A3 (en) 2001-08-28
KR19990063672A (en) 1999-07-26
NO981386L (en) 1998-05-28
PL325953A1 (en) 1998-08-17
TR199800573T2 (en) 1998-07-21
BG102355A (en) 1999-04-30
NZ319891A (en) 1999-01-28
AU716497B2 (en) 2000-02-24
AU7251596A (en) 1997-04-17
CN1201369A (en) 1998-12-09
JPH11512724A (en) 1999-11-02

Similar Documents

Publication Publication Date Title
AU1597795A (en) Method of enhancing the human immune system
EP0814846A4 (en) Gene therapy by secretory gland expression
EP0959893A4 (en) Stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
ZA90171B (en) Treatment methods and vaccines for stimulating an immune response
EP0851765A4 (en) Therapeutic and prophylactic methods using heat shock proteins
NO975730D0 (en) Method of increasing protective immune responses
PL314640A1 (en) Method of vaccinating against coccodiosis
HUP9800731A3 (en) Stimulation of meiosis
ZA985460B (en) Methods for inducing an immune response
AU3813395A (en) Method for gene therapy involving suppression of an immune response
HUP9802651A3 (en) Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
AU6459596A (en) Methods of treatment of neurological diseases by interferon antagonists
EP0858506A4 (en) Genetic induction of receptors for targeted radiotherapy
AU3179999A (en) Methods to treat undesirable immune responses
HK1014862A1 (en) Method for inducing humoral and cellular immune responses utilizing intracellular delivery of peptide-coated microparticles
AU4647993A (en) Method of stimulating the immune system
PL325413A1 (en) Novel 1-arylalkyl imidazolyn-2-ones of anticonvulsive action containing disubstituted amino radical at their fourth position and method of obtaining them
IL118538A0 (en) Oral immunization of pneumococcal antigens
ZA982579B (en) Method of stimulating nerve regeneration
EP0686039A4 (en) Method of enhancing immune response to oral vaccines
GB9503008D0 (en) Method of enhancing immune responses
AU5523196A (en) Methods and compositions for production of customized vaccines for diseases associated with antigens of microorganisms
AU7410496A (en) Method to increase and modify immune responses
IL117305A0 (en) Gene therapy of atherosclerosis by genetically modified monocytes
PL327172A1 (en) Method of purifying recombined human interleukin - 8

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980324

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 980324;LV PAYMENT 980324;SI PAYMENT 980324

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA FARBER CANCER INSTITUTE

Owner name: UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA FARBER CANCER INSTITUTE

Owner name: DANA FARBER CANCER INSTITUTE, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA FARBER CANCER INSTITUTE, INC.

Owner name: UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 47/02 B

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 39/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030723

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20031103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1015223

Country of ref document: HK